A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with relapse/refractory Acute Leukemia
Phase 1 other active
Quick answer
A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with relapse/refractory Acute Leukemia for Relapse/ refractory acute Leukemia is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Relapse/ refractory acute Leukemia
- Phase
- Phase 1
- Modality
- other
- Status
- active